Get the Stockscreener App
12.26
0.42%
-0.0516
After Hours:
12.26
Oculis Holding Ag stock is traded at $12.26, with a volume of 16,056.
It is down -0.42% in the last 24 hours and up +2.17% over the past month.
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
See More
Previous Close:
$12.31
Open:
$12.25
24h Volume:
16,056
Relative Volume:
0.74
Market Cap:
$511.80M
Revenue:
-
Net Income/Loss:
$-75.28M
P/E Ratio:
-8.6338
EPS:
-1.42
Net Cash Flow:
$-57.45M
1W Performance:
+2.59%
1M Performance:
+2.17%
6M Performance:
+1.74%
1Y Performance:
+11.45%
1-Day Range:
$12.15
$12.27
1-Week Range:
$11.90
$12.40
52-Week Range:
$9.05
$14.46
Oculis Holding Ag Stock (OCS) Company Profile
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-14-23 | Initiated | BofA Securities | Buy |
| Jun-12-23 | Initiated | H.C. Wainwright | Buy |
| Jun-08-23 | Initiated | Robert W. Baird | Outperform |
| May-10-23 | Initiated | Pareto | Buy |
| Apr-28-23 | Initiated | Wedbush | Outperform |
Oculis Holding Ag Stock (OCS) Latest News
Reviewing Oculis (NASDAQ:OCS) & Journey Medical (NASDAQ:DERM) - Defense World
Learn to Evaluate (OCS) using the Charts - Stock Traders Daily
Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award - StockTitan
Q3 2024 Earnings Forecast for Oculis Holding AG (NASDAQ:OCS) Issued By Leerink Partnrs - Defense World
Equities Analysts Offer Predictions for Oculis Holding AG's Q3 2024 Earnings (NASDAQ:OCS) - MarketBeat
Brokerages Set Oculis Holding AG (NASDAQ:OCS) Price Target at $30.17 - MarketBeat
Oculis Holding AG (NASDAQ:OCS) Given Average Recommendation of “Buy” by Analysts - Defense World
Oculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer - Yahoo Finance UK
Leerink Partners maintains Outperform tag on Oculis shares on positive portfolio update - Investing.com
Oculis to Present at Upcoming September Investor Conferences - Yahoo Finance UK
Oculis to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference - Yahoo Finance UK
Oculis Holding AG (NASDAQ:OCS) Short Interest Update - MarketBeat
Q3 2024 EPS Estimates for Oculis Holding AG (NASDAQ:OCS) Decreased by Analyst - MarketBeat
Oculis Holding AG (NASDAQ:OCS) to Post Q3 2024 Earnings of ($0.51) Per Share, HC Wainwright Forecasts - Defense World
Oculis Holding AG (NASDAQ:OCS) to Post Q1 2025 Earnings of ($0.49) Per Share, HC Wainwright Forecasts - MarketBeat
Oculis Holding AG (NASDAQ:OCS) to Post Q1 2025 Earnings of ($0.49) Per Share, HC Wainwright Forecasts - Defense World
Oculis to Present at Upcoming September Investor Conferences - GlobeNewswire
Oculis to Present at Upcoming September Investor Conferences - StockTitan
Oculis to Present at Upcoming September Investor Conferences - Yahoo Finance
(OCS) Investment Report - Stock Traders Daily
Analyst maintains its target on Oculis shares post-results - Investing.com
Oculis Holding AG (OCS) Reports Q2 Loss, Misses Revenue Estimates - MSN
Analyst maintains its target on Oculis shares post-results By Investing.com - Investing.com Canada
Oculis' (OCS) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Oculis (NASDAQ:OCS) Receives Buy Rating from HC Wainwright - Defense World
Analyst maintains its target on Oculis shares post-results By Investing.com - Investing.com UK
Oculis Reports 2024 Second Quarter Financial Results - Vision Monday
Oculis Publishes Consolidated Q2 Financial Statements and MD&A - Yahoo Finance UK
Oculis Holding Shows Strong Asset and Equity Growth - TipRanks
Oculis Publishes Consolidated Q2 Financial Statements and MD&A - StockTitan
Oculis Holding AG (OCS) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Oculis Reports Q2 2024 Financial Results and Provides Recent Company Update - Yahoo Finance UK
Oculis Reports Q2 Financial Results and Provides Recent Company Update - wallstreet:online
Oculis Reports Q2 2024 Financial Results and Provides Recent Company Update - wallstreet:online
Oculis (OCS) Scheduled to Post Quarterly Earnings on Tuesday - MarketBeat
Oculis (OCS) Set to Announce Quarterly Earnings on Tuesday - Defense World
Oculis Appoints Dr. Sharon Klier as Chief Development Officer - Vision Monday
Oculis names new Chief Development Officer to bolster eye care pipeline - Investing.com Canada
Oculis names new Chief Development Officer to bolster eye care pipeline - Investing.com
Oculis Appoints Dr. Sharon Klier As Chief Development Officer - Contract Pharma
Oculis names new Chief Development Officer to bolster eye care pipeline - Investing.com India
Oculis names new Chief Development Officer to bolster eye care pipeline - Investing.com UK
Oculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer - GlobeNewswire
Oculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer - Yahoo Finance
Short Interest in Oculis Holding AG (NASDAQ:OCS) Decreases By 18.5% - MarketBeat
Oculis Holding AG (NASDAQ:OCS) Sees Large Decrease in Short Interest - Defense World
Oculis Holding AG (NASDAQ:OCS) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Oculis Holding AG (NASDAQ:OCS) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Oculis (NASDAQ:OCS) Stock Price Up 0.9% - Defense World
Oculis (NASDAQ:OCS) Stock Price Up 0.9% - MarketBeat
(OCS) Investment Analysis - Stock Traders Daily
Oculis Holding Ag Stock (OCS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):